Track topics on Twitter Track topics that are important to you
US drugmaker Gilead Sciences has agreed to pay almost $12 billion to acquire compatriot Kite Pharma. Through the cash transaction, it will gain access to Car-T, Kite’s cutting-edge chimeric antigen therapy treatment for cancer. Both companies are based in California.
Original Article: Gilead to pay $12 Billion for Kite PharmaNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...